<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340088</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Vaccine Strategies among Healthcare Workers during COVID-19 Omicron Outbreak in Taiwan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1057</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091057</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to assess the reactogenicity and immunogenicity of various SARS-CoV-2 vaccines and compare their protective effects against COVID-19 among healthcare workers (HCWs) during the Omicron outbreak in Taiwan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Conducted from March 2021 to July 2023, this prospective observational study included healthy HCWs without prior COVID-19 immunization. Participants chose between adenovirus-vectored (AstraZeneca), mRNA (Moderna, BioNTech-Pfizer), and protein-based (Medigen, Novavax) vaccines. Blood samples were taken at multiple points to measure neutralizing antibody (nAb) titers, and adverse events (AEs) were recorded via questionnaires.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 710 HCWs, 668 (94.1%) completed three doses, and 290 (40.8%) received a fourth dose during the Omicron outbreak. AEs were more common with AstraZeneca and Moderna vaccines, while Medigen caused fewer AEs. Initial nAb titers were highest with Moderna but waned over time regardless of the vaccine. Booster doses significantly increased nAb titers, with the highest levels observed in Moderna BA1 recipients. The fourth dose significantly reduced COVID-19 incidence, with Moderna BA1 being the most effective.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Regular booster doses, especially with mRNA and adjuvant-protein vaccines, effectively enhance nAb levels and reduce infection rates, providing critical protection for frontline HCWs during variant outbreaks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Min-Ru</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chung-Guei</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0002-0598-5684</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Cheng-Hsun</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Infectious Diseases Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chih-Jung</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-5317-2461</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Infectious Diseases Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CORPG3L0171 and CORPG3L0172</GrantID><Agency>Chang Gung Memorial Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">effectiveness</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">reactogenicity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340088</ArticleId><ArticleId IdType="pmc">PMC11435596</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091057</ArticleId><ArticleId IdType="pii">vaccines12091057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gebru A.A., Birhanu T., Wendimu E., Ayalew A.F., Mulat S., Abasimel H.Z., Kazemi A., Tadesse B.A., Gebru B.A., Deriba B.S., et al. Global Burden of COVID-19: Situational Analyis and Review. Hum. Antibodies. 2021;29:139–148. doi: 10.3233/hab-200420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/hab-200420</ArticleId><ArticleId IdType="pubmed">32804122</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Solidarity Trial Vaccines.  [(accessed on 29 January 2022)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-covid-19-vaccines.</Citation></Reference><Reference><Citation>Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet. 2021;396:1979–1993. doi: 10.1016/s0140-6736(20)32466-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/s0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 MRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/nejmoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh S.-M., Liu M.-C., Chen Y.-H., Lee W.-S., Hwang S.-J., Cheng S.-H., Ko W.-C., Hwang K.-P., Wang N.-C., Lee Y.-L., et al. Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: Interim Results of a Large-Scale, Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial in Taiwan. Lancet Respir. Med. 2021;9:1396–1406. doi: 10.1016/s2213-2600(21)00402-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(21)00402-1</ArticleId><ArticleId IdType="pmc">PMC8514195</ArticleId><ArticleId IdType="pubmed">34655522</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine. N. Engl. J. Med. 2021;385:1172–1183. doi: 10.1056/nejmoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L., Haas E.J., Milo R., Alroy-Preis S., Ash N., Huppert A. Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med. 2021;385:e85. doi: 10.1056/nejmoa2114228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2114228</ArticleId><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Tessier E., Stowe J., Gower C., Kirsebom F., Simmons R., Gallagher E., Thelwall S., Groves N., Dabrera G., et al. Duration of Protection against Mild and Severe Disease by COVID-19 Vaccines. N. Engl. J. Med. 2022;386:340–350. doi: 10.1056/nejmoa2115481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2115481</ArticleId><ArticleId IdType="pmc">PMC8781262</ArticleId><ArticleId IdType="pubmed">35021002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyke K.E., Atmar R.L., Islas C.D., Posavad C.M., Szydlo D., Chourdhury R.P., Deming M.E., Eaton A., Jackson L.A., Branche A.R., et al. Rapid Decline in Vaccine-Boosted Neutralizing Antibodies against SARS-CoV-2 Omicron Variant. Cell Rep. Med. 2022;3:100679. doi: 10.1016/j.xcrm.2022.100679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100679</ArticleId><ArticleId IdType="pmc">PMC9212999</ArticleId><ArticleId IdType="pubmed">35798000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D., Sun Y., Xu H., Ye Q. The Emergence and Epidemic Characteristics of the Highly Mutated SARS-CoV-2 Omicron Variant. J. Méd. Virol. 2022;94:2376–2383. doi: 10.1002/jmv.27643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27643</ArticleId><ArticleId IdType="pmc">PMC9015498</ArticleId><ArticleId IdType="pubmed">35118687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.-C., Ko W.-C., Chen C.-J., Chen P.-Y., Huang Y.-C., Lee P.-I., Hsueh P.-R. COVID-19 Vaccines and Thrombosis with Thrombocytopenia Syndrome. Expert Rev. Vaccines. 2021;20:1027–1035. doi: 10.1080/14760584.2021.1949294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1949294</ArticleId><ArticleId IdType="pubmed">34176415</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterlini M. COVID-19: Sweden, Norway, and Finland Suspend Use of Moderna Vaccine in Young People “as a Precaution”. BMJ. 2021;375:n2477. doi: 10.1136/bmj.n2477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2477</ArticleId><ArticleId IdType="pubmed">34635488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon D. Omicron’s Molecular Structure Could Help Explain Its Global Takeover. Nature. 2022;602:373–374. doi: 10.1038/d41586-022-00292-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00292-3</ArticleId><ArticleId IdType="pubmed">35115694</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Tuttle K.S., Marquez A.C., Sekirov I., Subramaniam S. SARS-CoV-2 Omicron Variant: Antibody Evasion and Cryo-EM Structure of Spike Protein–ACE2 Complex. Science. 2022;375:760–764. doi: 10.1126/science.abn7760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7760</ArticleId><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.-M., et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532–1546. doi: 10.1056/nejmoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S., Champion J., Moultrie H., Bekker L.-G., Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N. Engl. J. Med. 2021;386:494–496. doi: 10.1056/nejmc2119270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2119270</ArticleId><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.-J., Yang L.-Y., Chang W.-Y., Huang Y.-C., Chiu C.-H., Shih S.-R., Huang C.-G., Huang K.-Y.A. A Randomized Controlled Trial of Heterologous ChAdOx1 NCoV-19 and Recombinant Subunit Vaccine MVC-COV1901 against COVID-19. Nat. Commun. 2022;13:5466. doi: 10.1038/s41467-022-33146-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33146-7</ArticleId><ArticleId IdType="pmc">PMC9482645</ArticleId><ArticleId IdType="pubmed">36115850</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall E.C., Wu M., Harvey R., Kelly G., Warchal S., Sawyer C., Daniels R., Hobson P., Hatipoglu E., Ngai Y., et al. Neutralising Antibody Activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 Vaccination. Lancet. 2021;397:2331–2333. doi: 10.1016/s0140-6736(21)01290-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01290-3</ArticleId><ArticleId IdType="pmc">PMC8175044</ArticleId><ArticleId IdType="pubmed">34090624</ArticleId></ArticleIdList></Reference><Reference><Citation>Atmar R.L., Lyke K.E., Deming M.E., Jackson L.A., Branche A.R., Sahly H.M.E., Rostad C.A., Martin J.M., Johnston C., Rupp R.E., et al. Homologous and Heterologous COVID-19 Booster Vaccinations. N. Engl. J. Med. 2022;386:1046–1057. doi: 10.1056/nejmoa2116414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2116414</ArticleId><ArticleId IdType="pmc">PMC8820244</ArticleId><ArticleId IdType="pubmed">35081293</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K., et al. Safety and Immunogenicity of Seven COVID-19 Vaccines as a Third Dose (Booster) Following Two Doses of ChAdOx1 NCov-19 or BNT162b2 in the UK (COV-BOOST): A Blinded, Multicentre, Randomised, Controlled, Phase 2 Trial. Lancet. 2021;398:2258–2276. doi: 10.1016/s0140-6736(21)02717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal J.L., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., Simmons R., Cottrell S., Roberts R., O’Doherty M., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on COVID-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D., Campisi J., Verdin E., Carrera-Bastos P., Targ S., Franceschi C., Ferrucci L., Gilroy D.W., Fasano A., Miller G.W., et al. Chronic Inflammation in the Etiology of Disease across the Life Span. Nat. Med. 2019;25:1822–1832. doi: 10.1038/s41591-019-0675-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0675-0</ArticleId><ArticleId IdType="pmc">PMC7147972</ArticleId><ArticleId IdType="pubmed">31806905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>